PRA Health Sciences Inc
Change company Symbol lookup
Select an option...
PRAH PRA Health Sciences Inc
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
DKS Dick's Sporting Goods Inc
Go

Health Care : Life Sciences Tools & Services | Mid Cap Growth
Company profile

PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

Closing Price
$109.93
Day's Change
-0.35 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
111.06
Day's Low
108.77
Volume
(Light)
Volume:
243,130

10-day average volume:
336,277
243,130

Company Profile

PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

Valuation Ratios

Price/Earnings (TTM)
33.66x
Price/Sales (TTM)
2.27x
Price/Book (MRQ)
6.02x
Price/Cash Flow (TTM)
20.94x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2020
Current Month
935.9K
Previous Month
972.5K
Percent of Float
1.47%
Days to Cover
3.1617 Days

Share Information

PRAH is in a share class of common stock
Float
63.8M
Shares Outstanding
64.0M
Institutions Holding Shares
404
97.91%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Colin ShannonChmn.
  • Michael J. BonelloCFO
  • Christopher L. GaenzleExec.VP
  • James C. Momtazee
  • Jeffrey T. Barber

Address

  • 4130 Parklake Ave Ste 400
  • Raleigh, NC 27612-4462
  • Phone: (919) 786-8200
  • Fax: (919) 786-8201
  • http://www.prahs.com

Insider Trading

During the most recent quarter, 13K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.